CAP-TEER: CerebrAl Protection During Transcatheter Edge-to-edge Repair
Condition(s) studied
Investigational drug(s) / intervention(s)
Cerebral Embolic Protection: Subjects will undergo M-TEER following placement of the cerebral embolic protection device.
Study summary
Transcatheter edge-to-edge repair of the mitral valve (M-TEER) is a well-established endovascular treatment option for patients with severe mitral regurgitation who are at high risk for surgery-related complications. However, the procedure carries a risk of clinically overt strokes and imaging-detected brain lesions, which may potentially be mitigated through the use of cerebral protection devices.
This prospective, multi-center, randomized, controlled study aims to assess the efficacy and safety of cerebral protection device, compared to a control group undergoing unprotected M-TEER.
Eligibility
Primary outcome measure(s)
- Total amounts of new lesions — 72 hours
Total amounts of new lesions in the brain assessed by diffusion weighted magnetic resonance imaging (DW-MRI) at 72 hours.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| The First Affiliated Hospital of Sun Yat-sen University | Guangzhou | Guangdong |
More Xiao-dong Zhuang trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06814210 on ClinicalTrials.gov ↗ ← All trials in China